144 related articles for article (PubMed ID: 36710485)
21. Development and Validation of a DNA Methylation-related Classifier of Circulating Tumour Cells to Predict Prognosis and to provide a therapeutic strategy in Lung Adenocarcinoma.
Gu X; Huang X; Zhang X; Wang C
Int J Biol Sci; 2022; 18(13):4984-5000. PubMed ID: 35982906
[No Abstract] [Full Text] [Related]
22. PAR2 Promoter Hypomethylation Regulates PAR2 Gene Expression and Promotes Lung Adenocarcinoma Cell Progression.
Wu K; Xu L; Cheng L
Comput Math Methods Med; 2021; 2021():5542485. PubMed ID: 33968158
[TBL] [Abstract][Full Text] [Related]
23. High GJB2 mRNA expression and its prognostic significance in lung adenocarcinoma: a study based on the TCGA database.
Tang Y; Zhang YJ; Wu ZH
Medicine (Baltimore); 2020 Apr; 99(14):e19054. PubMed ID: 32243356
[TBL] [Abstract][Full Text] [Related]
24. DNA methylation molecular subtypes for prognosis prediction in lung adenocarcinoma.
Xu D; Li C; Zhang Y; Zhang J
BMC Pulm Med; 2022 Apr; 22(1):133. PubMed ID: 35392867
[TBL] [Abstract][Full Text] [Related]
25. Aberrant CpG-methylation affects genes expression predicting survival in lung adenocarcinoma.
He W; Ju D; Jie Z; Zhang A; Xing X; Yang Q
Cancer Med; 2018 Nov; 7(11):5716-5726. PubMed ID: 30353687
[TBL] [Abstract][Full Text] [Related]
26. A prognostic predictor panel with DNA methylation biomarkers for early-stage lung adenocarcinoma in Asian and Caucasian populations.
Kuo IY; Jen J; Hsu LH; Hsu HS; Lai WW; Wang YC
J Biomed Sci; 2016 Aug; 23(1):58. PubMed ID: 27484806
[TBL] [Abstract][Full Text] [Related]
27. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
28. Genome‑wide investigation of the clinical significance and prospective molecular mechanisms of kinesin family member genes in patients with lung adenocarcinoma.
Zhang L; Zhu G; Wang X; Liao X; Huang R; Huang C; Huang P; Zhang J; Wang P
Oncol Rep; 2019 Sep; 42(3):1017-1034. PubMed ID: 31322267
[TBL] [Abstract][Full Text] [Related]
29. Identification of Prognostic DNA Methylation Signatures in Lung Adenocarcinoma.
Wang P; Xu G; Gao E; Xu Y; Liang L; Jiang G; Duan L
Oxid Med Cell Longev; 2022; 2022():8802303. PubMed ID: 35814273
[TBL] [Abstract][Full Text] [Related]
30. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of STING expression and methylation in lung adenocarcinoma based on bioinformatics analysis.
Lin Z; Liu Y; Lin P; Li J; Gan J
Sci Rep; 2022 Aug; 12(1):13951. PubMed ID: 35978045
[TBL] [Abstract][Full Text] [Related]
32. Identification of diagnostic DNA methylation biomarkers specific for early-stage lung adenocarcinoma.
Cai Q; Zhang P; He B; Zhao Z; Zhang Y; Peng X; Xie H; Wang X
Cancer Genet; 2020 Aug; 246-247():1-11. PubMed ID: 32805686
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
34. Role of endothelin receptor type B (EDNRB) in lung adenocarcinoma.
Wei F; Ge Y; Li W; Wang X; Chen B
Thorac Cancer; 2020 Jul; 11(7):1885-1890. PubMed ID: 32394530
[TBL] [Abstract][Full Text] [Related]
35. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma.
Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ
Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression.
Li H; Tong L; Tao H; Liu Z
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32031203
[TBL] [Abstract][Full Text] [Related]
37. FAM72 serves as a biomarker of poor prognosis in human lung adenocarcinoma.
Yu Y; Wang Z; Zheng Q; Li J
Aging (Albany NY); 2021 Mar; 13(6):8155-8176. PubMed ID: 33686947
[TBL] [Abstract][Full Text] [Related]
38. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
Cao K; Ling X; Jiang X; Ma J; Zhu J
Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897
[TBL] [Abstract][Full Text] [Related]
39. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
Wu C; Rao X; Lin W
Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
[TBL] [Abstract][Full Text] [Related]
40. Integrative bioinformatics analysis the clinical value of KMT5A in different subtypes of lung cancer.
Liu S; Tian W; Li B
Comput Biol Chem; 2022 Feb; 96():107603. PubMed ID: 34894606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
